Literature DB >> 26526566

Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.

Franziska Bootz1, Dario Neri2.   

Abstract

Antibody-cytokine fusion proteins, often referred to as immunocytokines, represent a novel class of biopharmaceutical agents that combine the disease-homing activity of certain antibodies with the immunomodulatory properties of cytokine payloads. Originally, immunocytokines were mainly developed for cancer therapy applications. More recently, however, the use of anti-inflammatory cytokines for the treatment of chronic inflammatory conditions and to treat autoimmune diseases has been considered. This review analyzes basic principles in the design of immunocytokines and describes the most advanced products in preclinical and clinical development.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26526566      PMCID： PMC5144993          DOI： 10.1016/j.drudis.2015.10.012

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  130 in total

Review 1.  Pro- and anti-inflammatory effects of IL-4: from studies in mice to therapy of autoimmune diseases in humans.

Authors:  T Biedermann; M Röcken
Journal:  Ernst Schering Res Found Workshop       Date:  2005

Review 2.  Near-infrared fluorescence: application to in vivo molecular imaging.

Authors:  Scott A Hilderbrand; Ralph Weissleder
Journal:  Curr Opin Chem Biol       Date:  2009-10-30       Impact factor: 8.822

3.  Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.

Authors:  Katharina Frey; Andjelija Zivanovic; Kathrin Schwager; Dario Neri
Journal:  Integr Biol (Camb)       Date:  2011-01-11       Impact factor: 2.192

4.  Biopharmaceutical benchmarks 2014.

Authors:  Gary Walsh
Journal:  Nat Biotechnol       Date:  2014-10       Impact factor: 54.908

5.  Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti-Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis.

Authors:  Peter Laverman; Tessa van der Geest; Samantha Y A Terry; Danny Gerrits; Birgitte Walgreen; Monique M Helsen; Tapan K Nayak; Anne Freimoser-Grundschober; Inja Waldhauer; Ralf J Hosse; Ekkehard Moessner; Pablo Umana; Christian Klein; Wim J G Oyen; Marije I Koenders; Otto C Boerman
Journal:  J Nucl Med       Date:  2015-04-09       Impact factor: 10.057

6.  A critical evaluation of the tumor-targeting properties of bispecific antibodies based on quantitative biodistribution data.

Authors:  Teresa Hemmerle; Sarah Wulhfard; Dario Neri
Journal:  Protein Eng Des Sel       Date:  2012-09-12       Impact factor: 1.650

7.  The secreted form of the p40 subunit of interleukin (IL)-12 inhibits IL-23 functions and abrogates IL-23-mediated antitumour effects.

Authors:  Osamu Shimozato; Shin-ichi Ugai; Masako Chiyo; Hisanori Takenobu; Hiroyasu Nagakawa; Akihiko Wada; Kiyoko Kawamura; Hiroshi Yamamoto; Masatoshi Tagawa
Journal:  Immunology       Date:  2006-01       Impact factor: 7.397

8.  Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix.

Authors:  Barbara Carnemolla; Laura Borsi; Enrica Balza; Patrizia Castellani; Raffaella Meazza; Alexander Berndt; Silvano Ferrini; Hartwig Kosmehl; Dario Neri; Luciano Zardi
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

9.  Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12.

Authors:  Roberto Sommavilla; Nadine Pasche; Eveline Trachsel; Leonardo Giovannoni; Christoph Roesli; Alessandra Villa; Dario Neri; Manuela Kaspar
Journal:  Protein Eng Des Sel       Date:  2010-06-15       Impact factor: 1.650

10.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

Authors:  Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green
Journal:  Arthritis Rheum       Date:  2006-01
View more
  26 in total

1.  Antibody-mediated delivery of VEGF-C potently reduces chronic skin inflammation.

Authors:  Simon Schwager; Silvana Renner; Teresa Hemmerle; Sinem Karaman; Steven T Proulx; Roman Fetz; Alexandra Michaela Golding-Ochsenbein; Philipp Probst; Cornelia Halin; Dario Neri; Michael Detmar
Journal:  JCI Insight       Date:  2018-12-06

Review 2.  Next generation antibody drugs: pursuit of the 'high-hanging fruit'.

Authors:  Paul J Carter; Greg A Lazar
Journal:  Nat Rev Drug Discov       Date:  2017-12-01       Impact factor: 84.694

Review 3.  Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins.

Authors:  Christian Fercher; Sahar Keshvari; Michael A McGuckin; Ross T Barnard
Journal:  Exp Biol Med (Maywood)       Date:  2017-12-19

4.  Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.

Authors:  Hans D Menssen; Ulf Harnack; Ulrike Erben; Dario Neri; Burkhard Hirsch; Horst Dürkop
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-11       Impact factor: 4.553

5.  An engineered 4-1BBL fusion protein with "activity on demand".

Authors:  Jacqueline Mock; Marco Stringhini; Alessandra Villa; Michael Weller; Tobias Weiss; Dario Neri
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-25       Impact factor: 11.205

Review 6.  Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation.

Authors:  Patrizia Murer; Dario Neri
Journal:  N Biotechnol       Date:  2019-04-13       Impact factor: 5.079

7.  Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads.

Authors:  Anja Sophie Schmid; Diana Tintor; Dario Neri
Journal:  J Biotechnol       Date:  2018-02-10       Impact factor: 3.307

8.  Antibody-based targeted delivery of interleukin-4 synergizes with dexamethasone for the reduction of inflammation in arthritis.

Authors:  Anja Sophie Schmid; Teresa Hemmerle; Francesca Pretto; Anja Kipar; Dario Neri
Journal:  Rheumatology (Oxford)       Date:  2018-04-01       Impact factor: 7.580

9.  Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.

Authors:  Roberto De Luca; Dario Neri
Journal:  Cancer Immunol Immunother       Date:  2018-07-04       Impact factor: 6.968

10.  Targeted Delivery of Cytotoxic Drugs: Challenges, Opportunities and New Developments.

Authors:  Samuele Cazzamalli; Alberto Dal Corso; Dario Neri
Journal:  Chimia (Aarau)       Date:  2017-10-25       Impact factor: 1.509
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.